Numerous studies have proven that methylation or dysregulation of ANRIL may lessen CDKN2A / B and its downstream tumor suppressants (p14ARF and p16INK4A), which main to tumor formation and progression [42]. This evidence concerns the gene CDKN2B-AS1 and neoplasm.